Transitioning from TPN to Oral or Enteral Nutrition

September 4, 2025

Understanding the Shift from Parenteral to Enteral and Oral Nutrition

Transitioning from total parenteral nutrition (TPN) to oral or enteral feeding is a critical step in patient recovery, requiring careful planning, assessment, and multidisciplinary collaboration. This article explores the scientific guidelines, clinical procedures, and best practices that underpin a safe and effective transition, aiming to optimize patient outcomes and nutritional adequacy.

Structured Approach to Transitioning from TPN

What are the guidelines for transitioning from TPN to oral or enteral nutrition?

The process of moving from Total Parenteral Nutrition (TPN) to oral or enteral feeding must be undertaken carefully and systematically. The standard procedure is to gradually reduce TPN over a period of 48 to 72 hours, allowing the gastrointestinal system time to adapt and assuming the patient shows signs of adequate tolerance.

A key goal during this transition is to ensure that enteral nutrition provides between 60% and 75% of the patient's total caloric and protein requirements. This amount can be adjusted based on ongoing assessments of the patient’s nutritional needs and clinical stability.

Healthcare teams typically initiate the transition once the patient demonstrates gastrointestinal readiness, such as the ability to tolerate the introduction of oral or enteral feeds, adequate bowel movements, and stable weight. The process involves a stepwise reduction in the volume of TPN while incrementally increasing enteral feeds. During this period, close monitoring for any signs of intolerance—such as increased gastric residuals, abdominal distension, diarrhea, vomiting, or aspiration—is essential.

Monitoring also includes tracking laboratory parameters, electrolyte balance, hydration status, and overall clinical indicators. If intolerance or complications arise, the transition may need to be slowed or temporarily halted.

The primary aim is to ensure continuous nutritional support that meets the patient's needs without overwhelming the digestive tract. Once the patient consistently tolerates enteral nutrition at the targeted levels, and meets 60-75% of their caloric and protein requirements through these feeds, TPN can be safely discontinued.

This gradual approach minimizes risks associated with abrupt changes, such as refeeding syndrome or malnutrition, and promotes gastrointestinal recovery and functional improvement.

In summary, the guidelines recommend a structured, closely monitored process that emphasizes patient safety, nutritional adequacy, and tolerance, with regular clinical assessments and adjustments as needed.

Protocols for Discontinuing TPN Safely

What protocols exist for discontinuing TPN?

Discontinuing total parenteral nutrition (TPN) is a critical step in patient recovery and requires careful planning to avoid complications. The general consensus among healthcare providers emphasizes a gradual reduction, or tapering, of TPN to smoothly transition the patient to enteral or oral feeding.

For long-term TPN use, protocols recommend slowly decreasing the infusion rate over several days. This gradual approach helps prevent hypoglycemia—a common concern when glucose supply is abruptly cut—and reduces the risk of metabolic disturbances.

In neonatal patients, specific guidelines suggest stopping TPN once enteral nutrition (EN) reaches about 140-150 ml/kg/day. The timing depends on individual clinical status, gastrointestinal function, and tolerance to enteral feeds.

In adult and pediatric populations, clinicians typically monitor various metabolic parameters—including blood glucose, electrolytes, liver enzymes, and acid-base status—during the weaning process. As the patient's tolerance improves, TPN is tapered in tandem with increasing enteral intake.

Although standardized, one-size-fits-all protocols are rare, most recommendations highlight an individualized approach. This involves assessing patient stability, nutritional requirements, and the ability to maintain adequate nutrition orally or enterally.

Throughout this process, clinical judgment and careful monitoring are vital. Signs of intolerance—such as hypoglycemia, electrolyte imbalance, or nutritional deficits—must be swiftly addressed. The overarching goal is to transition safely while maintaining optimal nutritional status.

In summary, TPN discontinuation protocols prioritize a cautious, stepwise reduction of infusion rate paired with close observation of metabolic parameters. Such approaches ensure smooth transition and minimize risks associated with abrupt cessation.

Aspect Typical Approach Considerations
Weaning Strategy Gradual reduction over days Monitoring for hypoglycemia, electrolyte stability
Metabolic Monitoring Regular checks of blood glucose, electrolytes, liver function, acid-base balance Detecting early signs of imbalance
Entry Criteria for Discontinuation Adequate enteral/oral intake reaching 50-75% of requirements, clinical stability Ensuring nutritional adequacy post-TPN removal
Neonatal Specifics Tapering when EN reaches ~140-150 ml/kg/day Based on individual tolerance

This approach underscores the importance of careful, individualized planning in the safe discontinuation of TPN, aiming to sustain nutritional needs while minimizing risks.

Comparison of TPN and Enteral Nutrition in Clinical Practice

How does TPN compare to enteral nutrition in terms of effectiveness and indications?

Total parenteral nutrition (TPN) and enteral nutrition (EN) are two distinct methods of providing nutritional support in clinical settings, each suited to different patient conditions. EN, often called tube feeding, involves delivering nutrients directly to the stomach or small intestine via a feeding tube. It is generally the preferred initial approach when the gastrointestinal (GI) tract is functioning properly.

The effectiveness of EN lies in its ability to maintain gut integrity, stimulate the immune response, and support the gut microbiome. It also minimizes risks associated with intravenous access, such as line infections. EN typically supports better overall clinical outcomes, including fewer infections — such as pneumonia and bacteremia — and shorter hospital stays.

On the other hand, TPN involves infusing a nutrient mixture directly into the bloodstream through a central or peripheral vein. It is indicated when the GI tract is non-functional or when enteral feeding cannot meet nutritional needs—examples include severe malabsorption, bowel obstructions, or significant gastrointestinal trauma.

While TPN is crucial in certain scenarios, it presents higher risks compared to EN. These include infections from central lines, metabolic disturbances like hyperglycemia or electrolyte imbalances, and liver complications such as cholestasis and fibrosis. Because of these risks, TPN is usually reserved for patients who cannot receive or tolerate enteral feeding.

Multiple clinical guidelines and research studies consistently favor early initiation of EN owing to its safety, cost-effectiveness, and positive impact on patient recovery. However, in cases where EN is contraindicated or insufficient, TPN provides an essential alternative to meet nutritional demands.

Impact on gut health and infection risk

Enabling the gut to process nutrients helps preserve its structure and function, preventing atrophy and supporting the microbiome diversity crucial for immune health.

Conversely, reliance solely on TPN without gut stimulation can lead to mucosal atrophy, loss of gut microbiota diversity, and bile acid circulation issues. These changes might increase the risk of infections and liver complications.

Infection risks are notably higher with TPN due to the necessity of invasive central intravenous access. The risk of bloodstream infections and line-related complications has been well-documented, emphasizing the importance of strict aseptic procedures.

The decision to use TPN or EN depends on a combination of patient-specific factors—including the condition of the GI tract, nutritional requirements, and risk profile—and ongoing clinical assessments.

Aspect Enteral Nutrition Parenteral Nutrition Additional Details
Effectiveness Supports gut integrity and immune function Bypasses GI, directly meets nutritional needs Guides clinical choice based on gut function
Indications Functional GI tract but unable to eat Non-functional GI tract or contraindications to EN Critical for malabsorption, bowel surgery
Safety Fewer complications, supports microbiome Higher infection and metabolic risk Requires careful management and monitoring
Impact on gut health Preserves mucosal integrity Risk of atrophy and microbiome loss Important for long-term outcomes
Infection risk Lower Higher, due to IV line use Emphasizes aseptic techniques

This comparison highlights the importance of tailored nutritional strategies based on individual patient profiles to optimize recovery and minimize complications.

Clinical Considerations and Patient Assessment

What is the typical process and clinical considerations involved in transitioning from TPN to oral or enteral nutrition?

Transitioning from Total Parenteral Nutrition (TPN) to oral or enteral nutrition requires a structured, patient-specific approach carried out over approximately 48 to 72 hours. Healthcare professionals begin by assessing the patient's current nutritional and clinical status, including their gastrointestinal (GI) functionality, stability, and tolerance to oral or enteral feeding.

The process involves gradually increasing the amount of enteral nutrition (EN) while decreasing TPN, ensuring that caloric and protein requirements are met without overwhelming the GI system. During this period, clinicians carefully monitor for signs of intolerance such as increased gastric residual volume, bloating, diarrhea, vomiting, or abdominal distension.

Patients typically need to reach a point where they can tolerate at least 60-75% of their prescribed caloric and protein needs through EN before discontinuing TPN completely. This margin helps prevent nutritional deficits and supports gut integrity. The transition also aims to prevent complications like refeeding syndrome, which can occur if nutrition is reintroduced too rapidly.

Throughout this process, multidisciplinary teams—including physicians, dietitians, and nursing staff—collaborate to ensure safe progression. They utilize clinical judgment, assessment tools, and frequent monitoring to tailor the transition plan, ensuring it aligns with the patient's individual stability, nutrition needs, and tolerance levels.

How can clinicians assess a patient's readiness for nutritional transition?

Assessing a patient's readiness involves comprehensive evaluation of their nutritional, physical, and psychological status. Clinicians often use standardized assessment tools such as the Transition Readiness Assessment Questionnaire (TRAQ), which helps measure confidence, knowledge, and preparedness as reported by both patients and caregivers.

Beyond tools, clinicians measure physical parameters like weight stability, body mass index (BMI), serum vitamin and mineral levels, and other laboratory markers to determine nutritional adequacy. Evaluating gastrointestinal (GI) function through assessment of bowel sounds, residual volumes, and the absence of significant nausea or vomiting is crucial.

Medical history is reviewed for factors that may influence readiness, such as ongoing infections, metabolic disturbances, or comorbidities. Psychological readiness and emotional maturity are also considered, ensuring the patient and family are prepared for self-feeding.

The care team engages the patient in shared decision-making, setting realistic goals tailored to individual circumstances. Gradual introduction of enteral feeds, starting from clear liquids progressing to more complex formulas, provides opportunities to evaluate tolerance.

Continuous monitoring of clinical signs—including weight, intake/output, laboratory tests, and gastrointestinal tolerance—guides ongoing adjustments. This dynamic assessment helps identify any issues early and supports a safe, effective transition from TPN to self-managed feeding.

Best Practices and Multidisciplinary Management

How do healthcare teams contribute to the transition from TPN to oral or enteral nutrition?

Managing the shift from parenteral nutrition (PN) to enteral or oral feeding is a complex process that benefits greatly from a team-based approach. Multidisciplinary teams, often referred to as Nutrition Support Teams (NSTs), are essential for developing and implementing effective transition plans. These teams typically consist of healthcare professionals such as dietitians, nurses, physicians, and sometimes pharmacists or speech-language pathologists.

Their collaborative efforts focus on providing comprehensive nutritional assessments, planning individualized transition strategies, and ensuring safe administration of nutrients during the process. By monitoring patients closely, they help prevent complications like aspiration, refeeding syndrome, or nutritional deficits. These teams also coordinate education for patients and caregivers, lay out protocols for gradual weaning, and regularly evaluate progress through clinical and laboratory data.

Such coordinated care not only promotes safety and efficacy but also aligns with established guidelines, reducing the risk of hospital readmissions and improving patient outcomes.

What are best practices for safely weaning a patient off TPN?

A safe and effective transition off TPN requires careful planning and monitoring. First, clinicians must assess the patient’s gastrointestinal function, ensuring that the gut is capable of tolerating enteral or oral intake. This involves evaluating gastrointestinal motility, residuals, and the presence of symptoms such as nausea or distension.

The weaning process should be gradual, typically reducing TPN calories stepwise while increasing enteral or oral intake. This approach prevents metabolic disturbances, refeeding syndrome, and other complications. Regular monitoring includes tracking weight, electrolyte levels, blood glucose, and gastrointestinal tolerance. Adjustments are made based on clinical responses.

Addressing symptoms like nausea or diarrhea swiftly can facilitate smoother transition. Involving a multidisciplinary team ensures that nutritional plans are tailored to the patient’s needs, preferences, and medical condition, optimizing safety during the weaning process.

What factors influence the success of a nutrition transition?

The success of transitioning from TPN to enteral or oral intake depends on several factors. Clinical stability, gastrointestinal readiness, and nutritional status are primary. Patients with preserved gut function, minimal active infections, and stable metabolic control are more likely to tolerate transition.

Age, presence of inflammation, and underlying conditions such as metastatic cancer may impact appetite and the ability to establish adequate oral intake. Conversely, hunger often correlates with a greater likelihood of successful transition, as observed in some clinical studies.

Additional considerations include the patient’s psychological readiness, social support, and adherence to the nutrition plan. Regular assessment and individualized care plans are essential for addressing these variables.

How is monitoring integrated into the transition process?

Monitoring is integral to ensuring successful and safe nutrition transition. Key areas include:

  • Gastrointestinal tolerance: Watch for symptoms like distension, diarrhea, vomiting, or gastric residuals.
  • Nutritional adequacy: Track caloric and protein intake compared to prescribed needs.
  • Laboratory tests: Regularly check electrolytes, blood glucose, liver function tests, and other pertinent labs.
  • Weight and physical status: Monitor weight changes and muscular mass for signs of malnutrition or overfeeding.
  • Complication signs: Be vigilant for infections related to catheter use, aspiration risks, or metabolic disturbances.

This ongoing assessment guides adjustments in the nutrition plan, ensures timely intervention when issues arise, and supports a smooth transition from PN to enteral/oral feeding.

How do multidisciplinary teams implement structured care during transition?

Implementation begins with developing protocols rooted in clinical guidelines and best practices. Healthcare teams conduct comprehensive patient assessments, including nutritional, medical, and psychosocial parameters. They establish stepwise plans to introduce oral or enteral feeds, starting with low residue diets or clear liquids.

Education and training for staff, patients, and families are vital to foster understanding and adherence. The team closely monitors tolerance and makes real-time modifications as necessary.

Periodic reviews, audits, and data collection help refine practices and promote continuous improvement. Effective communication within the team ensures that all members are informed, coordinated, and proactive in managing potential complications.

Summarized overview of patient management during the transition

Aspect Practice Description
Assessment Evaluate GI function, nutritional status, and readiness Essential before initiating transition
Gradual reduction Taper TPN while increasing enteral/oral intake Prevents metabolic disturbances
Monitoring Regular labs, weight, tolerance evaluation Ensures safety and progress
Team collaboration Multidisciplinary planning and review Facilitates individualized, safe transition
Emergency preparedness Protocols for complications like aspiration or refeeding syndrome Quick response minimizes adverse outcomes

By implementing these practices, healthcare providers can optimize the transition process, balancing nutritional needs with patient safety.

Summary and Future Directions in Nutritional Transition

The shift from TPN to oral or enteral nutrition is a nuanced process that hinges on careful patient assessment, structured protocols, and coordinated multidisciplinary efforts. Emphasizing gradual progression, vigilant monitoring, and individualized strategies helps mitigate complications and promotes nutritional recovery. As research advances, developing standardized guidelines and leveraging innovative assessment tools will further enhance safety and efficacy in nutritional transition, ultimately improving patient outcomes across diverse clinical settings.

References

Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Show More